Ginsenoside Rh2 Yellow crystalline purity 98% BONTAC Rh2

• 
  

• Ginsenosides are the main active substances of the traditional Chinese medicine ginseng.

• The secondary metabolites of the transformed ginsenosides have stronger biological activity, which is called rare ginsenosides.

• Ginsenosides Rh2 and Rg3 are PPD-type rare ginsenosides respectively with 1 and 2 glucose groups on the C3 hydroxyl group of PPD.

• * Promote sexual function and anti aging
• 
  
• 
  
  * Reduce fatigue and strengthen the body's vitality
• 
  
• 
  
  * Anti platelet agglutination, prevent cerebral thrombosis
• 
  
• 
  
  * Anti-radiation, anti-genetic and immune damage
• 
  
• 
  
  * Protect nerve cells, prevent Alzheimer's disease
• 
  
• 
  
  * Enhance the immunity of the body against disease invasion
• 
  
• 
  
  * Prevent cardiovascular diseases by improving myocardial ischemia
• 
  
• 
  
  * Improve the anti - tumor ability, increase the effect of radiotherapy and chemotherapy and reduce the toxicity
• 
  
• 
  
• 
  

• • * Enhance the immune function of the human body: Ginsenoside Rh2 has the effect of enhancing the immune function of the patient's body. After taking this active ingredient, the patient's immune function will be improved, thereby alleviating the pain he suffered during the treatment.
     
    • * Promote the synthesis of albumin: Ginsenoside Rh2 acts as an immune regulator to promote the synthesis of albumin, which can provide heat for the human body, protect and stabilize the immunoglobulin in the blood.
     
    • * Inhibit the growth of tumor cells: Because ginsenoside Rh2 can effectively reduce the toxicity left by chemotherapy in the human body by improving immunity, ginsenoside RH2 can effectively reduce the pain of patients after chemotherapy,and the active ingredient can also inhibit the continuous growth of tumor cancer cells in the body..
     
    • * Reversal of abnormal tumor differentiation: Ginsenoside RH2 has a differentiation-inducing effect on tumor cancer cells, and can effectively enhance the melanin production ability in cancer cells, thereby causing cancer cells to transform into normal cells in morphology.
    • 
      
    
    
    

Packaging: 

• Aluminum foil bag
• Food grade PE bag 
• Carton box 
• Drum 

Transport conditions:
Keep sealed, dry and protected from light for transportation under room temperature

Storage conditions: 
Keep dry and away from light, long term storage at -25℃ to -15℃     

• • * Beverages Health
   
  • * Care products
   
  • * Wine
   
  • * Cosmetic
   
  • * Drug
   
  • * Daily chemical product
   
  • * Snacks
   
  • * Functional food

  • 
    

BONTAC NAD+ PRODUCT FEATURES AND ADVANTAGES:

• * Provide one-stop product solution customization service

  * Multiple patents and strict third-party self-inspection

  * The first national mass production of ginsenosides by enzymatic synthesis, with pure raw materials, higher conversion rate and higher content, up to 99%

  * The unique Bonzyme enzymatic synthesis technology, which can accurately synthesize both S-type and R-type isomers, resulting in stronger activity and precise targeting action

• 
  

• 
  

• Ginsenoside Rh2 exerts anticancer effects in vitro and in vivo, and is a promising agent for cancer prevention and treatment.

•  

  

• • Ginsenoside Rh2 has a wide range of pharmacological effects and plays a therapeutic role in numerous diseases. A number of studies have demonstrated that Ginsenoside Rh2 exerts excellent anticancer activity in vitro and in vivo. Mechanically, Ginsenoside Rh2 exerts its anticancer activity by inducing apoptosis, autophagy, cell cycle arrest and immunity, as well as by inhibiting proliferation, invasion, metastasis and angiogenesis. In addition, Ginsenosid Rh2 in combination with specific anticancer drugs can overcome drug resistance and enhance the immune response.

• Rerefence
•  
• Zhang, H., Park, S., Huang, H., Kim, E., Yi, J., Choi, S. K., Ryoo, Z., & Kim, M. (2021). Anticancer effects and potential mechanisms of ginsenoside Rh2 in various cancer types (Review). Oncology reports, 45(4), 33. https://doi.org/10.3892/or.2021.7984
•